2008-07-04 20:57:18 -
www.companiesandmarkets.com adds new report - Monoclonal Antibodies Report Part 1 www.companiesandmarkets.com/Summary-Market-Report/Monoclonal-Ant ..
Introduction
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Scope
Comprehensive financial strategic analysis of the mAb
market out to 2012
Global sales forecasts to 2012 for all marketed and Phase III mAb products
Analysis of market trends by product, company, therapy area, technology and target type
Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics
Highlights
The overall ethical pharmaceutical market is expected to face a decline in sales over 2011 to 2012 as a result of the ´patent cliff´. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.
Over the period 2006-12, the mAb market segment will achieve a sales CAGR of 14.2% versus a small molecule sales CAGR of 0.6%. The main barrier to sales growth for small molecules is exposure to material generic competition, which will have no effect on mAbs out to 2012.
mAbs currently command a two-fold average revenue per product premium over small molecules. Positive factors supporting this premium include a higher demand due to addressing therapy areas of high unmet need and lower competitive intensity due to accessing novel target space.
Reasons to Purchase
Assess the key products that will drive sales growth in the mAb market to 2012
Understand the challenges and barriers to entry for new players seeking to venture into the mAb market
Understand the nature of the generic threat across different molecule types and the insulation of mAb products from biosimilars out to 2012
